Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Lancet Neurology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1474-4422(14)70262-5PMID 25467848
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HD‐CAB: A cognitive assessment battery for clinical trials in Huntington's disease1,2,3

  2014cited by this paper
• A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease.

  2013cited by this paper
• Huntington disease arises from a combinatory toxicity of polyglutamine and copper binding

  2013cited by this paper
• HTRF analysis of soluble huntingtin in PHAROS PBMCs

  2013cited by this paper
• Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.

  2013cited by this paper
• Prefrontal activity in Huntington's disease reflects cognitive and neuropsychiatric disturbances: the IMAGE-HD study.

  2013cited by this paper
• A novel approach to rapidly prevent age-related cognitive decline

  2013cited by this paper
• Natural history of Huntington disease.

  2013cited by this paper
• PBT2 Reduces Toxicity in a C. elegans Model of polyQ Aggregation and Extends Lifespan, Reduces Striatal Atrophy and Improves Motor Performance in the R6/2 Mouse Model of Huntington's Disease

  2012cited by this paper
• Alterations in brain transition metals in Huntington disease: an evolving and intricate story.

  2012cited by this paper
• An evidence-based approach in the treatment of Huntington's disease.

  2012cited by this paper
• The Trail Making Test in prodromal Huntington disease: Contributions of disease progression to test performance

  2011cited by this paper
• Cysteine Oxidation within N-terminal Mutant Huntingtin Promotes Oligomerization and Delays Clearance of Soluble Protein*

  2011cited by this paper
• The Alzheimer’s therapeutic PBT2 promotes amyloid‐β degradation and GSK3 phosphorylation via a metal chaperone activity

  2011cited by this paper
• The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.

  2011cited by this paper
• A randomized, placebo-controlled trial of latrepirdine in Huntington disease.

  2010cited by this paper
• Randomized Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington Disease

  2009cited by this paper
• Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta.

  2008cited by this paper
• Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic.

  2008cited by this paper
• Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.

  2008cited by this paper
• Intrinsic fluctuations within cortical systems account for intertrial variability in human behavior.

  2007cited by this paper
• Are Cognitive Changes Progressive in Prediagnostic HD?

  2007cited by this paper
• Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG

  2006cited by this paper
• Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model.

  2005cited by this paper
• The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment

  2005cited by this paper
• Unified Huntington's disease rating scale: reliability and consistency

  1996cited by this paper
• Unified Huntington's disease rating scale: Reliability and consistency

  1996cited by this paper
• The Neuropsychiatric Inventory

  1994cited by this paper
• A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

  1993cited by this paper
• Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk.

  1986cited by this paper
• Increased rate of suicide among patients with Huntington's disease.

  1984cited by this paper
• Letter: Tryptophan plus a pyrrolase inhibitor for depression?

  1975cited by this paper
• Relation between subacute myelo-optic neuropathy (S.M.O.N.) and clioquinol: nationwide survey.

  1973cited by this paper
• Glycogen Synthase Kinase-3 (cid:1) Inhibitors Prevent Cellular Polyglutamine Toxicity Caused by the Huntington’s Disease Mutation*

  year unknowncited by this paper

• Microglial, astrocytic, oligodendrocyte, B-/T-cell and neutrophil dysregulation in neuroinflammation of Alzheimer's disease and related dementias.

  2026cites this paper
• High energy resolution fluorescence detected X-ray absorption spectroscopy (HERFD-XAS) for studies of metals and metalloids in biology: current innovations and future perspectives

  2025cites this paper
• Highlights of the chemistry and pharmacological potential of 8-hydroxyquinoline: a review

  2025cites this paper
• Metals in medicine: unlocking new avenues for neurodegenerative disease treatment

  2025cites this paper
• Nano-conjugation of small molecule modulators of protein aggregation: Enhancing the therapeutic precision.

  2025cites this paper
• Copper homeostasis and cuproptosis: implications for neurodegenerative diseases

  2025cites this paper
• Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases

  2025cites this paper
• Mechanisms, therapeutic uses, and developmental perspectives of redox-active thiomolybdates

  2025cites this paper
• Polyglutamine disorders: Pathogenesis and potential drug interventions.

  2024cites this paper
• Membraneless organelles in health and disease: exploring the molecular basis, physiological roles and pathological implications

  2024cites this paper
• Targeting Metals in Alzheimer’s Disease: An Update

  2024cites this paper
• New applications of clioquinol in the treatment of inflammation disease by directly targeting arginine 335 of NLRP3

  2024cites this paper
• Evidence-Based Review on Symptomatic Management of Huntington’s Disease

  2024cites this paper
• Advances in Clinical Therapies for Huntington's Disease and the Promise of Multi‐Targeted/Functional Drugs Based on Clinicaltrials.gov

  2024cites this paper
• What Huntington’s Disease Patients Say About Their Illness: An Online Direct-to-Participant Pilot Study

  2024cites this paper
• [Toward the complete understanding of the pathogenic mechanism of clioquinol-induced subacute myelo-optic neuropathy (SMON)].

  2024cites this paper
• Overlapping Neuroimmune Mechanisms and Therapeutic Targets in Neurodegenerative Disorders

  2023cites this paper
• From zinc homeostasis to disease progression: Unveiling the neurodegenerative puzzle.

  2023cites this paper
• Insights Into the Role of Copper in Neurodegenerative Diseases and the Therapeutic Potential of Natural Compounds

  2023cites this paper
• A clinical study and future prospects for bioactive compounds and semi-synthetic molecules in the therapies for Huntington's disease

  2023cites this paper
• Repurposing Sunscreen as an Antibiotic: Zinc-Activated Avobenzone Inhibits Methicillin-Resistant Staphylococcus aureus.

  2023cites this paper
• From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington’s Disease Research

  2023cites this paper
• Advances in iPSC Technology in Neural Disease Modeling, Drug Screening, and Therapy.

  2023cites this paper
• Iron and Ferroptosis More than a Suspect: Beyond the Most Common Mechanisms of Neurodegeneration for New Therapeutic Approaches to Cognitive Decline and Dementia

  2023cites this paper
• Metals to combat antimicrobial resistance

  2023cites this paper
• Therapeutic targeting of Huntington's disease: Molecular and clinical approaches.

  2023cites this paper
• Metals to combat antimicrobial resistance

  2023cites this paper
• Small molecules to perform big roles: The search for Parkinson's and Huntington's disease therapeutics

  2023cites this paper
• An MDS Evidence‐Based Review on Treatments for Huntington's Disease

  2022cites this paper
• Next-Generation Polymyxin Class of Antibiotics: A Ray of Hope Illuminating a Dark Road

  2022cites this paper
• Accidental Falls in Patients with Hyperkinetic Movement Disorders: A Systematic Review

  2022cites this paper
• Alzheimer's Drug PBT2 Interacts with the Amyloid β 1-42 Peptide Differently than Other 8-Hydroxyquinoline Chelating Drugs.

  2022cites this paper
• Repurposing the Ionophore, PBT2, for Treatment of Multidrug-Resistant Neisseria gonorrhoeae Infections

  2022cites this paper
• Clioquinol as an inhibitor of JmjC-histone demethylase exhibits common and unique histone methylome and transcriptome between clioquinol and hypoxia

  2022cites this paper
• Design, Synthesis, and In Vitro Evaluation of Novel 8-Amino-Quinoline Combined with Natural Antioxidant Acids

  2022cites this paper
• Current and Possible Future Therapeutic Options for Huntington’s Disease

  2022cites this paper
• Neurodegenerative Disease Treatment Drug PBT2 Breaks Intrinsic Polymyxin Resistance in Gram-Positive Bacteria

  2022cites this paper
• Electrospun 5-Chloro-7-iodo-8-hydroxyquinoline (Clioquinol)-Containing Poly(3-hydroxybutyrate)/Polyvinylpyrrolidone Antifungal Materials Prospective as Active Dressings against Esca

  2022cites this paper
• Recent developments in the management of Huntington's disease.

  2022cites this paper
• Dysregulation of Streptococcus pneumoniae zinc homeostasis breaks ampicillin resistance in a pneumonia infection model

  2022influential citation
• Rescuing Tetracycline Class Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii Pulmonary Infection

  2022cites this paper
• Disruption of Metallostasis in the Anaerobic Human Pathogen Fusobacterium nucleatum by the Zinc Ionophore PBT2.

  2021cites this paper
• Iron Chelation in Movement Disorders: Logical or Ironical

  2021cites this paper
• The antimicrobial and immunomodulatory effects of Ionophores for the treatment of human infection.

  2021cites this paper
• Novel Antimicrobial 8-Hydroxyquinoline-Based Agents: Current Development, Structure-Activity Relationships, and Perspectives.

  2021cites this paper
• Alterations in metal homeostasis occur prior to canonical markers in Huntington disease

  2021cites this paper
• A systematic literature review of web-based student response systems: Advantages and challenges

  2021cites this paper
• Theoretical Three-Dimensional Zinc Complexes with Glutathione, Amino Acids and Flavonoids

  2021cites this paper
• A drug candidate for Alzheimer's and Huntington's disease, PBT2, can be repurposed to render Neisseria gonorrhoeae susceptible to natural cationic antimicrobial peptides.

  2021cites this paper
• Cognitive decline in Huntington’s disease in the Digitalized Arithmetic Task (DAT)

  2021cites this paper
• Role of Iron in the Molecular Pathogenesis of Diseases and Therapeutic Opportunities.

  2021cites this paper
• Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities

  2020cites this paper
• Multiple Bactericidal Mechanisms of the Zinc Ionophore PBT2

  2020cites this paper
• Substituted sulfonamide bioisosteres of 8-hydroxyquinoline as zinc-dependent antibacterial compounds.

  2020cites this paper
• Polyphenols as Potential Metal Chelation Compounds Against Alzheimer’s Disease

  2020cites this paper
• Targeting zinc metalloenzymes in coronavirus disease 2019

  2020cites this paper
• Therapeutic Update on Huntington’s Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies

  2020cites this paper
• Solution Chemistry of Copper(II) Binding to Substituted 8-Hydroxyquinolines.

  2020cites this paper
• An alloy of zinc and innate immunity: Galvanising host defence against infection

  2020cites this paper
• Montreal Cognitive Assessment for evaluating cognitive impairment in Huntington's disease: a systematic review.

  2020cites this paper
• Biomedical applications of copper ionophores

  2020cites this paper
• PBT2 acts through a different mechanism of action than other 8-hydroxyquinolines: an X-ray fluorescence imaging study.

  2020cites this paper
• Repurposing a neurodegenerative disease drug to treat Gram-negative antibiotic-resistant bacterial sepsis

  2020cites this paper
• C-2 derivatized 8-sulfonamidoquinolines as antibacterial compounds.

  2020cites this paper
• Copper(II) Binding to PBT2 Differs from That of Other 8-Hydroxyquinoline Chelators: Implications for the Treatment of Neurodegenerative Protein Misfolding Diseases.

  2020cites this paper
• A Neurotoxic Ménage-à-trois: Glutamate, Calcium, and Zinc in the Excitotoxic Cascade

  2020cites this paper
• Montreal cognitive assessment for evaluating cognitive impairment in Huntington’s disease: a systematic review

  2020cites this paper
• Biological Evaluation of 8-Hydroxyquinolines as Multi-Target Directed Ligands for Treating Alzheimer's Disease.

  2019cites this paper
• Is Huntington's disease on the threshold of a new era in treatment?

  2019cites this paper
• Brain Zinc Deficiency Exacerbates Cognitive Decline in the R6/1 Model of Huntington’s Disease

  2019cites this paper
• State biomarkers for Machado Joseph disease: Validation, feasibility and responsiveness to change

  2019cites this paper
• Emerging therapies in Huntington’s disease

  2019cites this paper
• The choice not to undergo genetic testing for Huntington disease: Results from the PHAROS study

  2019cites this paper
• Clioquinol: To harm or heal.

  2019cites this paper
• Lysosomal dysfunction in proteinopathic neurodegenerative disorders: possible therapeutic roles of cAMP and zinc

  2019cites this paper
• Psychopharmacotherapy in Patients with Tics and Other Motor Disorders

  2019cites this paper
• Neisseria gonorrhoeae Becomes Susceptible to Polymyxin B and Colistin in the Presence of PBT2.

  2019cites this paper
• Oral clioquinol is effective in the treatment of a fly model of Candida systemic infection

  2019cites this paper
• Recent advances in the therapeutic development for Huntington disease.

  2019cites this paper
• Huntington disease: A quarter century of progress since the gene discovery.

  2019cites this paper
• Chemical Synergy between Ionophore PBT2 and Zinc Reverses Antibiotic Resistance

  2018cites this paper
• Huntington's disease: Current and future therapeutic prospects

  2018cites this paper
• Clioquinol is a promising preventive morphological switching compound in the treatment of Candida infections linked to the use of intrauterine devices

  2018cites this paper
• Therapeutic approaches to Huntington disease: from the bench to the clinic

  2018cites this paper
• The pharmacological perturbation of brain zinc impairs BDNF-related signaling and the cognitive performances of young mice

  2018cites this paper
• Clinical Features of Huntington's Disease.

  2018cites this paper
• New insights into the mechanism of antifungal action of 8-hydroxyquinolines

  2018cites this paper
• Huntington's disease: a clinical review

  2018cites this paper
• New Perspectives in Iron Chelation Therapy for the Treatment of Neurodegenerative Diseases

  2018cites this paper
• Huntington disease.

  2018cites this paper
• Optimisation of transplantation methodology in mouse models of Huntington's Disease

  2018cites this paper
• New directions in therapeutics for Huntington disease.

  2018cites this paper
• Metal Protein-Attenuating Compound for PET Neuroimaging: Synthesis and Preclinical Evaluation of [11C]PBT2.

  2018cites this paper
• Metals and Alzheimer’s Disease: How Far Have We Come in the Clinic?

  2018cites this paper
• Evaluation of 8‐Hydroxyquinoline Derivatives as Hits for Antifungal Drug Design

  2017cites this paper
• New symptomatic therapies for Huntington disease.

  2017cites this paper
• Cognitive assessment in Huntington disease clinical drug trials.

  2017cites this paper
• Cardiac Light Chain Amyloidosis: The Role of Metal Ions in Oxidative Stress and Mitochondrial Damage

  2017cites this paper
• Metal Biology Associated with Huntington’s Disease

  2017cites this paper
• Plant Metabolites and More Treating Various Ailments

  2017cites this paper